Live Attenuated Vaccines for RSV and COVID-19
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV). These vaccine candidates have been developed using the company’s proprietary AttenuBlock synthetic biology and codon deoptimization platform. Meissa’s vaccine candidates are formulated to be delivered as an intranasal, adjuvant-free, needle-free dose and are designed to prevent infection and disease and generate a strong, durable immune response.
AttenuBlock: Optimized Immunity
RSV and SARS-CoV-2 are both life-threatening respiratory viruses that inhibit the immune system. Meissa’s AttenuBlock platform generates vaccine candidates that are safe, highly attenuated and specifically optimized to induce a better immune response than natural infection.